Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Williams %R



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 34 10.9 0.56% 1.27% 11.8% -7.0% 119.3%
SHORT 35 12.3 0.46% 0.84% 5.0% -8.2% -75.0%


Technical Analysis

Developed by Larry Williams, Williams %R is a momentum indicator that is the inverse of the Fast Stochastic Oscillator. Also referred to as %R Williams %R reflects the level of the close relative to the highest high for the look-back period.

Calculation: Williams %R:
1) %R = (Highest High - Close)/(Highest High - Lowest Low) * -100;
2) Lowest Low = lowest low for the look-back period Highest High = highest high for the look-back period %R is multiplied by -100 correct the inversion and move the decimal;

PROFILE: Ra Pharmaceuticals Inc (RARX)

Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Williams %R

Company Close Change(%) Volume Value Signal
SYRS Syros Pharmaceuticals 8.2 4.9 153,243 44.2 NEUTRAL
XENT Intersect Ent 25.17 4.7 1,131,415 26.6 NEUTRAL
TRUP Trupanion Inc 33.32 4.2 261,897 59.7 NEUTRAL
CCRN Cross Country Healthcare 10.85 3.9 684,096 36.5 NEUTRAL
SILC Silicom 36.49 3.4 22,305 20.1 NEUTRAL
CYTK Cytokinetics 12.54 3.3 413,412 23.3 NEUTRAL
OTIC Otonomy Inc 3.65 3.1 161,652 60.9 NEUTRAL
VRAY Viewray Inc 3.06 3 3,697,594 69.8 NEUTRAL
ACIU AC Immune 9.65 2.7 62,564 24 NEUTRAL
SGEN Seattle Genetics Inc 111.53 2.6 396,484 31.3 NEUTRAL